Identifying drivers of β-lactam/β-lactamase inhibitor resistance emergence and spread before their clinical deployment.

ABSTRACT: Understanding the landscape of resistance to antibiotics before their clinical deployment could inform strategies to slow the development of resistance upon their introduction. We evaluated the associations between bacterial genotypes, patient clinical characteristics, and medical exposures with resistance to two recently approved β-lactam/β-lactamase inhibitor combinations in carbapenem-resistant Klebsiella pneumoniae collected before their clinical deployment. Whole-genome sequencing revealed that even within the clonal sequence type 258, genetic background influenced baseline resistance levels and the propensity for resistance to emerge and spread. Resistance in ST258 clade II was mediated by convergent mutation at a small number of loci, which rarely spread amongst patients. In

SUBMITTER: Gontjes KJ 

PROVIDER: S-EPMC12324637 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature